Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs
Inhibiting thrombosis without inducing bleeding is a major challenge for anticoagulant agents. Here the authors describe a synthetic FXIIa inhibitor able to efficiently prevent thrombosis in mice and suppress coagulation in artificial lungs in rabbits without increasing the risk of bleeding.
Main Authors: | Jonas Wilbs, Xu-Dong Kong, Simon J. Middendorp, Raja Prince, Alida Cooke, Caitlin T. Demarest, Mai M. Abdelhafez, Kalliope Roberts, Nao Umei, Patrick Gonschorek, Christina Lamers, Kaycie Deyle, Robert Rieben, Keith E. Cook, Anne Angelillo-Scherrer, Christian Heinis |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-08-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-17648-w |
Similar Items
-
Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides
by: Alessandro Zorzi, et al.
Published: (2017-07-01) -
FXII: The Cuckoo in the Nest
by: Roger E.G. Schutgens
Published: (2018-12-01) -
The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant
by: Fernando Corvillo, et al.
Published: (2020-09-01) -
Development of Protein-Catalyzed Capture (PCC) Agents with Application to the Specific Targeting of the E17K Point Mutation of AKt1
by: Deyle, Kaycie Marie
Published: (2014) -
Polymorphism FXII 46C>T and cardiovascular risk: additional data from Spanish and Tunisian patients
by: Torres Robert, et al.
Published: (2009-07-01)